Please login to the form below

Not currently logged in

Investigation into Merck & Co drug

The US Food and Drugs Administration announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The US Food and Drugs Administration (FDA) announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The FDA has said that is investigation a possible association between the use of the drug and suicidal behaviour and thinking after analysing the most up-to-date information pertaining to the use of Singulair.

Singulair is a leukotriene receptor antagonist indicated for the treatment of patients with asthma and symptoms of allergic rhinitis and to prevent exercise-induced asthma.

The FDA said: "Until further information is available, healthcare professionals and caregivers should monitor patients taking Singulair for suicidality (suicidal thinking and behaviour) and changes in behaviour and mood."

The FDA did, however, caution that "patients should not stop taking Singulair before talking to their doctor if they have questions about this new information."

Evaluation of the date and the possible link between Singulair and suicidal behaviour and thinking may take up to nine months at which point the FDA's findings will be made available to the public.

27th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...